Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Marta Martin-Richard
Based on 3 articles published since 2009
(Why 3 articles?)
||||

Between 2009 and 2019, Marta Martín-Richard wrote the following 3 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Guideline [Recommendations for the diagnosis, staging and treatment of pre-malignant lesions and pancreatic adenocarcinoma]. 2016

Martin-Richard, Marta / Ginès, Angels / Ayuso, Juan Ramón / Sabater, Luis / Fabregat, Joan / Mendez, Ramiro / Fernández-Esparrach, Glòria / Molero, Xavier / Vaquero, Eva C / Cuatrecasas, Miriam / Ferrández, Antonio / Maurel, Joan / Anonymous3560884. ·Servicio de Oncología Médica, Hospital Sant Pau, Barcelona, España. Electronic address: mmartinri@santpau.cat. · Servicio de Gastroenterología, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Barcelona, España. · Servicio de Radiología, Hospital Clínic de Barcelona, Barcelona, España. · Servicio de Cirugía, Hospital Clínico Universitario de Valencia, Valencia, España. · Servicio de Cirugía, Hospital de Bellvitge, Barcelona, España. · Servicio de Radiología, Hospital Clínico San Carlos, Madrid, España. · Servicio de Gastroenterología, Hospital Vall d'Hebron, Barcelona, España. · Servicio de Anatomía Patológica, Hospital Clínic de Barcelona, Barcelona, España. · Servicio de Anatomía Patológica, Hospital Clínico Universitario de Valencia, Valencia, España. · Servicio de Oncología Médica, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, España; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, España. ·Med Clin (Barc) · Pubmed #27726847.

ABSTRACT: BACKGROUND AND OBJECTIVE: Clinical management of adenocarcinoma of the pancreas is complex, and requires a multidisciplinary approach. The same applies for the premalignant lesions that are increasingly being diagnosed. The current document is an update on the diagnosis and management of premalignant lesions and adenocarcinoma of the pancreas. PATIENTS AND METHODS: A conference to establish the basis of the literature review and manuscript redaction was organized by the Grupo Español Multidisciplinar en Cáncer Digestivo. Experts in the field from different specialties (Gastroenterology, Surgery, Radiology, Pathology, Medical Oncology and Radiation Oncology) met to prepare the present document. RESULTS: The current literature was reviewed and discussed, with subsequent deliberation on the evidence. CONCLUSIONS: Final recommendations were established in view of all the above.

2 Clinical Trial Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial). 2018

Maurel, Joan / Sánchez-Cabús, Santiago / Laquente, Berta / Gaba, Lydia / Visa, Laura / Fabregat, Joan / Povés, Ignacio / Roselló, Susana / Díaz-Beveridge, Roberto / Martín-Richard, Marta / Rodriguez, Javier / Sabater, Luis / Conill, Carles / Cambray, María / Reig, Ana / Ayuso, Juan Ramón / Valls, Carlos / Ferrández, Antonio / Bombí, Josep Antoni / Ginés, Angels / García-Albéniz, Xabier / Fernández-Cruz, Laureano. ·Medical Oncology Department, Hospital Clínic, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, University of Barcelona, Barcelona, Spain. jmaurel@clinic.cat. · Surgical Department, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. · Medical Oncology Department, Institut Català d'Oncologia, Hospitalet, Spain. · Medical Oncology Department, Hospital Clínic, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, University of Barcelona, Barcelona, Spain. · Department of Oncology, Hospital Mar, Barcelona, Spain. · Surgical Department, Hospital Bellvitge, Hospitalet, Spain. · Surgical Department, Hospital del Mar, Barcelona, Spain. · Medical Oncology Department, Hospital Clínico Valencia, Valencia, Spain. · Medical Oncology Department, Hospital La Fe, Valencia, Spain. · Medical Oncology Department, Hospital Sant Pau, Barcelona, Spain. · Medical Oncology Department, Hospital Clínico Universitario Navarra, Pamplona, Spain. · Surgical Department, Hospital Clínico Valencia, Valencia, Spain. · Radiotherapy Oncology Department, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. · Radiotherapy Oncology Department, Institut Català d'Oncologia, Hospitalet, Spain. · Radiotherapy Oncology Department, Hospital Mar, Barcelona, Spain. · Radiology Department, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. · Radiology Department, Hospital Bellvitge, Hospitalet, Spain. · Pathology Department, Hospital Clínico Valencia, Valencia, Spain. · Pathology Department, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. · Gastrointestinal Department, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. · Harvard T.H. Chan School of Public Health, Boston, MA, USA. · Surgical Department, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. lfcruz@clinic.cat. ·Cancer Chemother Pharmacol · Pubmed #30225601.

ABSTRACT: BACKGROUND: Neoadjuvant therapy (NAT) for pancreatic adenocarcinoma (PDAC) patients has shown promising results in non-randomized trials. This is a multi-institutional phase II trial of NAT in resectable PDAC patients. METHODS: Patients with confirmed resectable PDAC after agreement by two expert radiologists were eligible. Patients received three cycles of GEM (1000 mg/m RESULTS: Twenty-five patients were enrolled. Adverse effects of NAT were mainly mild gastrointestinal disorders. Resectability rate was 76%, with a R0 rate of 63.1% among the resected patients. Median overall survival (OS) and disease-free survival (DFS) were 23.8 (95% CI 11.4-36.2) and 12.8 months (95% CI 8.6-17.1), respectively. R0 resection patients had better median OS, compared with patients with R1 resection or not resected (65.5 months vs. 15.5 months, p = 0.01). N0 rate among the resected patients was 63.1%, and showed a longer median OS (65.5 vs. 15.2 months, p = 0.009). CONCLUSION: The results of this study confirm promising oncologic results with NAT for patients with resectable PDAC. Therefore, the present trial supports the development of phase II randomized trials comparing NAT vs. upfront surgery in resectable pancreatic cancer.

3 Article SPARC gene variants predict clinical outcome in locally advanced and metastatic pancreatic cancer patients. 2017

Arqueros, Cristina / Salazar, Juliana / Arranz, M J / Sebio, Ana / Mora, Josefina / Sullivan, Ivana / Tobeña, María / Martín-Richard, Marta / Barnadas, Agustí / Baiget, Montserrat / Páez, David. ·Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, C/Sant Quintí, 89, 08026, Barcelona, Spain. · Department of Genetics, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. · CIBERER U-705, Barcelona, Spain. · Fundació Docència i Recerca Mútua Terrassa, Terrassa, Spain. · Department of Biochemistry, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. · Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, C/Sant Quintí, 89, 08026, Barcelona, Spain. dpaez@santpau.cat. ·Med Oncol · Pubmed #28687963.

ABSTRACT: Secreted protein acidic and rich in cysteine (SPARC) is a glycoprotein of the extracellular matrix whose expression can be altered in malignant pancreatic cells and in the adjacent stromal fibroblasts. We evaluated the possible role of SPARC gene variants as prognostic markers for locally advanced and metastatic pancreatic cancer. We analyzed eight tagging single-nucleotide polymorphisms (TagSNPs) in the SPARC gene in 74 patients with pancreatic ductal adenocarcinoma treated with chemotherapy alone or combined with radiotherapy. TagSNPs were chosen using the HapMap genome browser and Haploview software 4.2 based on two predefined criteria: (1) coefficient cutoff of 0.80 and (2) minor allele frequency (MAF) ≥ 0.10. Univariate analyses revealed significant associations between four SNPs (rs17718347, rs2347128, rs3210714, and rs967527) and PFS. The rs3210714 genetic variant was also associated with OS. In the multivariate analyses, rs17718347 (HR 0.4; 95% CI 0.2-0.8; p = 0.013) and rs2347128 (HR 0.5; 95% CI 0.3-0.9; p = 0.049) remained statistically associated with PFS. In addition, patients harboring the T-A-G haplotype (rs17718347, rs1978707, rs2347128) had a better PFS (p = 0.002). Our findings suggest that SPARC polymorphisms may be useful in predicting outcome in patients with locally advanced and metastatic pancreatic cancer.